Peptide data sheet
AOD-9604
Performance · AOD9604 · Anti-Obesity Drug 9604 · hGH fragment 176-191 · Tyr-hGH 177-191
Verdict
unprovenThe unproven label is generous, not harsh: AOD-9604 has a clean early-safety record and a tidy animal-model story, but the human obesity trials that were supposed to prove fat loss did not beat placebo, so the headline benefit people chase remains unestablished rather than confirmed.
Quick answer
AOD-9604 is a synthetic peptide copied from the tail end of human growth hormone, the region linked to fat metabolism. It is commonly researched for fat loss and body composition without the growth-promoting effects of full growth hormone. Animal work looked promising, but the human obesity trials did not show meaningful weight loss over placebo. It is not FDA-approved and is sold for research use only.
- Class
- Modified growth-hormone fragment (hGH 176-191 analogue), lipolytic peptide
- Half-life
- short, on the order of minutes to a few hours (reported)
- FDA status
- Not FDA-approved. Studied in clinical trials for obesity but never approved for any use; sold for laboratory research use only.
- WADA banned?
- Yes
Which form actually works?
Injectable (subcutaneous)
Unproven
The form used in the clinical obesity trials and the one most research references. This is where the human data lives, and it is also where the trial disappointment lives: injections were generally well tolerated in early studies, but the expected fat-loss advantage over placebo did not materialize.
Oral / topical
Risky
Marketed by some sellers as capsules or creams, but there is essentially no controlled human evidence that a peptide this fragile survives digestion or crosses skin intact to do anything. Treat oral and topical claims as unsupported by the research.